IQV · Iqvia Holdings Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $932M | Q1 2026 | — |
|
|
|||
| Book-to-bill ratio | 1.04 | Q1 2026 | — |
|
|
|||
| Free Cash Flow non-GAAP | $491M | Q1 2026 | — |
|
|
|||
| R&D Solutions contracted backlog | 34.2B | Q1 2026 | — |
| R&D Solutions Net New Bookings | 2.5B | Q1 2026 | — |
| Trailing-twelve-month book-to-bill ratio | 1.11 | Q1 2026 | — |
| R&D Solutions quarterly bookings | $2.7B | the fourth quarter | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IQV
this stock
Iqvia Holdings Inc.
|
$34.60B | -8.0% | +41.6% | 25.8 | 3.0% |
|
TMO
Thermo Fisher Scientific Inc.
|
$212.69B | -1.1% | +0.4% | 31.5 | 1.4% |
|
DHR
Danaher Corp /De/
|
$135.32B | -15.6% | +8.5% | 34.1 | 1.5% |
|
IDXX
Idexx Laboratories Inc /De
|
$42.55B | -20.3% | +10.4% | 39.7 | 2.5% |
|
A
Agilent Technologies, Inc.
|
$39.47B | +3.1% | +6.4% | 28.1 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IQV | -1.5% | +11.7% | -12.0% | +7.3% | -8.0% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | +0.2% | +11.0% | -18.4% | +8.5% | -16.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.